

**Overview**

[Ncardia](http://ncardia.com) is a human-induced pluripotent stem cell (iPSC) technology company with facilities and clients throughout Europe and North America. Its mission is to enable biopharmaceutical companies in drug discovery and cell therapy to better integrate human iPSC technologies in their development process and bring better therapies to patients faster.

The company’s cell model portfolio includes hiPSC-derived cardiovascular, neural and immune cells. Building on this expertise, Ncardia provides a comprehensive menu of cardiovascular and neuronal services for drug discovery - from disease modeling to drug efficacy screening and cardiac safety assessment. For cell therapy developers, Ncardia partners to innovate iPSC-derived advanced therapies.

Since its founding, Ncardia has built the expertise and infrastructure required to differentiate, manufacture and characterize iPSC-derived cell models for drug discovery and cell therapy. The combination of stem cell biology knowledge and in-house technologies comprises the Ncardia iPSC Platform. Through this platform, the company provides tailored discovery services and partners with cell therapy developers to establish the next generation of advanced therapeutics.

Ncardia provides a broad portfolio of cardiovascular and neural iPSC services for safety and efficacy testing and analysis. Its integrated Drug Discovery platform provides a flexible solution for bringing hiPSC disease models into predictive assays suitable for drug discovery (screening) campaigns. The safety services are pre-configured service packages based on electrophysiology, biochemistry and contraction assay technology for predictive safety pharmacology and toxicology testing.

Ncardia partners with cell therapy clients to co-develop novel therapeutics that utilize stem cell technologies. With more than a decade of experience in the development, commercial manufacture and characterization of iPSC-derived cell models, the Ncardia team brings a deep knowledge of stem cell biology to its clients. Additionally, the company has a continuously growing IP portfolio that provides unique licensing opportunities in the stem cell space.